PLx Pharma — Investor Presentation (September 2017)
25 slides from PLx Pharma's investor presentation, Sep 28, 2017
Slide 1: PLx Pharma Inc. Corporate Presentation
@) PLx Pharma Inc. Corporate Presentation Nasdaq: PLXP
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. These statements relate to
Slide 3: PLx Pharma is focused on developing and commercializing next-generation oral NSAIDs
PLx Pharma is focused on developing & commercializing next-generation oral NSAIDs and other drugs that leverage our proprietary PLxGuard technology to achieve greater efficacy and improved safety versus current in-market oral products 2 ‘September 2017,
Slide 4: About PLx Pharma
About PLx Pharma ‘wee Novel drug delivery technology pa * Applicable to a variety of APIs ‘eee Lead product: Aspertec™ * Late-stage product opportunity * OTC product with 2 doses: 325mg (approved via 505(b)(2) NDA) and 81mg (sNDA to be filed mid 1H ’18) * Targeting YE 2018 launch in cardiovascular m
Slide 5: PLx Management Team
PLx Management Team Michael (Mike) J. Valentino + 35+ years CEO and senior management with successful OTC and Rx brands Rasolltive Chaamnan the Pears + OTC brand, Mucinex® (~$2.3 billion exit in 4.5 years) i me Mucinex §9 ita Xenodyne Natasha Giordano + 20+ years CEO and senior management commercial
Slide 6: Independent Board of Directors
Independent Board of Directors Name Gary S. Balkema Experience Former global head of Bayer Healthcare LLC and Worldwide Consumer Care Division At Bayer USA, repositioned aspirin after ten year decline into a growing business Prior VP and General Manager for American Cyanamid Co.'s Lederle Consumer H
Slide 7: Aspertec: Targeting an Unmet Medical Need
WACMUMAWPOOALUA OKT AY EY H MAUL) ical Need Aspertec: Targeting an Unmet Medical
Slide 8: Aspertec: Targeting an Unmet Medical Need
Aspertec: Targeting an Unmet Medical Need 34% of U.S. Population Falls in GI complications from NSAIDs Categories for which Aspirin limit compliance Would be Recommended + 50+ million people who could benefit from aspirin use are left vulnerable to cardiovascular events 1. US. Census Bureau estimate
Slide 9: Current Aspirin Landscape
Current Aspirin Landscape Widespread usage * Aspirin is one of the most widely-used drugs in the world Global standard of care * Foundational drug used to treat and prevent the leading cause of death, cardiovascular disease Compliance limitations * Gastrointestinal (Gl) upset / intolerability limits
Slide 10: Published Studies Support Aspirin - not EC Aspirin
Published Studies Support Aspirin - not EC Aspirin >200 studies support aspirin benefit EVERY important clinical study supporting cardiovascular benefit of aspirin was conducted using immediate release (not EC) aspirin? JAMA Dec 2014: Japanese study in >14,000 high-risk primary prevention subjects c
Slide 11: Why Does EC Aspirin Induce Gastric Ulceration?
Why Does EC Aspirin Induce Gastric Ulceration? Unidirectional Protection Gastroduodenal Reflux Stomach iad EC aspirin tablet intact in stomach (pH 3); no initial surface injury Duodenum EC aspirin disintegrates in duodenum (pH 5.5); Free Aspirin vadene Partially-dissolved EC free aspirin refluxes ia
Slide 12: Novel Delivery System: PLxGuard
Novel Delivery System: PLxGuard Utilizes surface acting lipids to selectively release drugs in targeted portions of the Gl tract Delivers better, more reliable absorption and antiplatelet efficacy Mechanism of action enables strong patent life September 2017
Slide 13: Aspertec Clinically Demonstrates Better Absorption & Antiplatelet Efficacy than EC Aspirin
Aspertec Clinically Demonstrates Better Absorption & Antiplatelet Efficacy than EC Aspirin soon COMmparison of Single Dose Aspirin Absorption Incidence of Complete Aspirin Response 90.0% 83.6% 2 2 Aspertee eof 80.0% 2 1500 EC Caplet patients stents 70.0% ae complete 60.0% 3 : 1000 aa sta wae Zo ~25%
Slide 14: Aspertec Clinically Demonstrates Better Absorption & Antiplatelet Efficacy than EC Aspirin
Aspertec Clinically Demonstrates Better Absorption & Antiplatelet Efficacy than EC Aspirin Aspirin Antiplatelet Response Hazard Ratio (95%C!) Index Period —e—_ P< 0.0001 11 days P< 0.0001 4 days 4 2 0 2 4 6 8 10 = Same as EC = EC Aspirin Better ‘aspirin AspertecBetter Aspertec 325 mg EC Aspirin 3-5X
Slide 15: Aspertec Has Better Acute GI Safety
* Aspirn's Surface Injur Aspirin induces corrosive damage by direct contact with the gastric surface - 12.0% manifested as ulceration and bleeding Endoscopy demonstrates EC aspirin is not gec¢ patents 8.0% p=0.004 Gl safer, with no difference in ulcer risk _withulcersin a thestomach 6.0% compared to
Slide 16: Aspertec: Unlocking Aspirin's Full Potential
Aspertec: Unlocking Aspirin’s Full Potential ‘ma Differentiated Marketing Claims ————————————_ + 3-5 times greater chance of complete antiplatelet effect than EC aspirin + In head-to-head clinical trials with EC aspirin, Aspertec 325 mg provided faster acting, more reliable, predictable and sustaina
Slide 17: Aspertec Market Opportunity: High Risk Patients
Aspertec Market Opportunity: High Risk Patients Aspertec Initially Targets Four Sizeable U.S. Patient Populations Secondary Coronary Artery Disease (CAD) Prevention Patients who have previously had a CAD event including ‘+ Myocardial Infarction (Mi) * Coronary Artery Bypass Graft (cae) + Percutaneou
Slide 18: Physicians Indicate High Intent to Prescribe Aspertec
Physicians Indicate High Intent to Prescribe Aspertec Quantitative and qualitative research completed with >1,000 cardiologists, interventional cardiologists, neurologists, endocrinologists/diabetologists and 2,000 consumers Aspirin Therapy Prescribers Endocrinologists Cardiologists Neurologists Dia
Slide 19: How Doctors Would Prescribe Aspertec
How Doctors Would Prescribe Aspertec Aspirin Therapy Prescribers Endocrinologists Cardiologists Neurologists _Diabetologists Number of Physicians: 201 100 100 104 Patients who have had a 1 i cardiovascular incident/heart 183% 78% 87% 83% attack 1 1 T Patients who have had a cerebral Iran ex mm | 46%
Slide 20: Positioning Aspertec as the Standard of Care
Positioning Aspertec as the Standard of Care * Clinical Data Support: — Faster acting than EC aspirin Potential to be — Better antiplatelet efficacy Best-in-class for than EC aspirin Acute Coronary — Better acute GI safety when initiating Syndrome (ACS) dual antiplatelet therapy ° Market Segmentatio
Slide 21: National Launch: Target Audience
National Launch: Target Audience Physician Specialists * 33,000 physicians - Highly targetable specialty universe: Cardiologists, Neurologists, Endocrinologists/Diabetologists — Top 3-5 Deciles write 75-85% of all prescriptions — Total Targets: 12,000 - 15,000 physician specialists — Field reps are
Slide 22: Pipeline Leverages PLxGuard Platform Technology
Pipeline Leverages PLxGuard Platform Technology PLxGuard Applicable to a Variety of APIs PL1200 Ibuprofen, 200mg | orc Pain, Inflammation and Fever OTC PL5100 Diclofenac, 50mg | (ie) PL1100 Ibuprofen, 400 mg Pain, Inflammation, Osteoarthritis Rx and Rheumatoid Arthritis PL4100 Indomethacin Rx /IV Pa
Slide 23: Upcoming Milestones
Upcoming Milestones Submit sNDA for Aspertec 81mg Mid 1H 2018 Pre-launch acti S * Create an esteemed Scientific Advisory Board to engage the scientific community * Expand commercial leadership team + Advance commercially oriented PK/PD study: Aspertec 81 mg * Hire and train initial at-launch 45 pers
Slide 24: Why PLx? Why Now?
Why PLx? Why Now? Key catalysts in next 12-18 ¢ sNDA filing for Aspertec 81mg planned for mid 1H 2018 ¢ PDUFA date for Aspertec 81mg expected 2H 2018 © Q4 2018 launch for both Aspertec 325mg and 81mg Clinical data support positioning Aspertec as best-in-class aspirin product within $12+ billion addr
Slide 25: Thank you
SET iia TOU entail i EON ANH Heyy Thank you